Immunity to mumps before and after MMR vaccination at 12 years of age in the first generation offered the two-dose immunization programme

Sweden was the first country in the world to introduce a two-dose programme of vaccination against measles, mumps and rubella with a combined vaccine (MMR). It was commenced in 1982 and the vaccination was carried out at the ages of 18 months and 12 years. In 1992–1993 the first age-group vaccinated...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 1998-01, Vol.16 (2), p.323-327
Main Authors: Broliden, Kristina, Abreu, Elba Rubilar, Arneborn, Malin, Böttiger, Margareta
Format: Article
Language:English
Subjects:
Biological and medical sciences
booster
Child
Epidemiology. Vaccinations
Female
General aspects
Humans
Immunization Programs
Immunization Schedule
Immunization, Secondary
Infectious diseases
Male
Measles Vaccine - administration & dosage
Measles Vaccine - immunology
Measles-Mumps-Rubella Vaccine
Medical sciences
mumps
Mumps - immunology
Mumps - prevention & control
Mumps Vaccine - administration & dosage
Mumps Vaccine - immunology
Rubella Vaccine - administration & dosage
Rubella Vaccine - immunology
Rubulavirus - immunology
Sweden
vaccination
Vaccines, Combined - administration & dosage
Vaccines, Combined - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sweden was the first country in the world to introduce a two-dose programme of vaccination against measles, mumps and rubella with a combined vaccine (MMR). It was commenced in 1982 and the vaccination was carried out at the ages of 18 months and 12 years. In 1992–1993 the first age-group vaccinated at 18 months reached the age of 12 and accordingly received a second dose of MMR. A total of 382 children participated in the present study. Sero-immunity against mumps was studied by testing neutralizing antibodies using serial dilutions inoculated into cell cultures before and after the 12-year vaccination. Of the 229 children earlier vaccinated (group A), 27% lacked demonstrable antibodies before the booster. Of those without documented vaccination records (group B), 56% were seronegative before vaccination. After vaccination, 93% of group A and 86% of group B were seropositive (titre ⩾2). In the seronegative children, whether vaccinated earlier or not, the seroconversion was ca 75%. Previously unvaccinated children positive before vaccination and thus likely to be naturally immune had a higher mean-titre both before and after vaccination than the seropositive chlidren earlier vaccinated. So far, the two-dose programme has proceeded as expected.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(97)88332-6